|The full article is available to subscribers||Subscriber Login|
The FDA has now approved a recombinant, 9-valent, human papillomavirus (HPV) vaccine (Gardasil 9 – Merck) for use in girls and women 9-26 years old and boys 9-15 years old. The new vaccine is indicated to prevent diseases associated with infection with HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which include genital warts and cervical, vulvar, vaginal, and anal precancerous lesions and cancer. Two recombinant HPV vaccines are already available in the US: Gardasil prevents disease associated with HPV types 6, 11, 16, and 18,1 and Cervarix prevents disease associated with HPV types 16 and 18.2
HPV INFECTION — HPV is commonly acquired by young women soon after initiation of sexual activity, with a cumulative incidence of 40% within 16 months. Although most HPV infections clear spontaneously without clinical... more
- A human papillomavirus vaccine. Med Lett Drugs Ther 2006; 48:65.
- Cervarix – a second HPV vaccine. Med Lett Drugs Ther 2010; 52:37.
- B Serrano et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012; 7:38.
- A Chatterjee. The next generation of HPV vaccines: nonavalent vaccine V503 on the horizon. Expert Rev Vaccines 2014; 13:1279.
- EA Joura et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372:711.
- LE Markowitz et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05):1.
- LE Markowitz. Proposed HPV vaccination recommendations. ACIP presentation slides: February 26, 2015 meeting. Available at: www.cdc.gov. Accessed March 19, 2015.